Meeting
2018 ASCO Annual Meeting
The potential cost-effectiveness of first-line immunotherapy + chemotherapy for advanced non-squamous non-small cell lung cancer (NSCLC).
Authors
Joshua A. Roth
Fred Hutchinson Cancer Research Center, Seattle, WA
Joshua A. Roth , Trung Nguyen , Bernardo H. L. Goulart
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research, Clinical Informatics, and Quality of Care
Track
Quality Care/Health Services Research
Sub Track
Value/Cost of Care
Citation
J Clin Oncol 36, 2018 (suppl; abstr 6612)
DOI
10.1200/JCO.2018.36.15_suppl.6612
Abstract #
6612
Poster Bd #
437
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 1b/2a safety and tolerability study of bemcentinib (BEM) with pembrolizumab/carboplatin/pemetrexed in first line (1L) advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without/with a STK11 mutation.
First Author: Rajwanth Veluswamy
Poster
2023 ASCO Annual Meeting
Phase II results of ivonescimab (AK112/ SMT112), a novel PD-1/VEGF bispecific, in combination with chemotherapy for first line treatment of advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA) in EGFR/ALK.
First Author: Li Zhang
Poster
2023 ASCO Annual Meeting
Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab.
First Author: Martin Reck
Poster
2022 ASCO Annual Meeting
A randomized, double-blind, phase 3 trial of MK-7684A plus chemotherapy versus pembrolizumab plus chemotherapy as first-line therapy for metastatic non–small cell lung cancer (NSCLC): KeyVibe-007.
First Author: Marina Chiara Garassino